Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H16N2O2 |
| Molecular Weight | 208.2569 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCC1=CC=C2OCOC2=C1)NN
InChI
InChIKey=IBWPUTAKVGZXRB-UHFFFAOYSA-N
InChI=1S/C11H16N2O2/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10/h4-6,8,13H,2-3,7,12H2,1H3
| Molecular Formula | C11H16N2O2 |
| Molecular Weight | 208.2569 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s. Safrazine and electroconvulsive therapy were shown to be effective in the treatment of antidepressant-resistant depressions (ARD) but had the drawbacks of the high incidence of moderate or severe adverse reactions and high relapse rates, respectively. The use of safrazine was discontinued.
Approval Year
Sample Use Guides
Nocturnal periodic hypoxemia occurring in a 25-year-old Duchenne muscular dystrophy patient under NIPPV control was successfully treated with monoamine oxydase inhibitor (MAOI), safrazine hydrochloride. Five mg of safrazine hydrochloride was administered before sleep, and the periodic hypoxemia disappeared within 14 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:43:45 GMT 2025
by
admin
on
Mon Mar 31 18:43:45 GMT 2025
|
| Record UNII |
F5G0P5378C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60860006
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
C013242
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
DB09253
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
34042
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
33419-68-0
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
Safrazine
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
100000078388
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
C84141
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
SUB15175MIG
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
F5G0P5378C
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
